Srs Capital Advisors, Inc. Exelixis, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 914 shares of EXEL stock, worth $24,038. This represents 0.0% of its overall portfolio holdings.
Number of Shares
914
Previous 550
66.18%
Holding current value
$24,038
Previous $13,000
53.85%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding EXEL
# of Institutions
460Shares Held
240MCall Options Held
2.04MPut Options Held
1.29M-
Black Rock Inc. New York, NY33.5MShares$881 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$780 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$713 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$399 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$331 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $8.46B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...